PDF(Pubmed)
Abstract：
Background: A debate persists on the prognostic value of the pre-therapeutic standardized uptake value (SUV) of non-tumorous lung tissue for the risk assessment of therapy-related pneumonitis, with most studies lacking significant correlation. However, the influence of patient comorbidities on the pre-therapeutic lung SUV has not yet been systematically evaluated. Thus, we aimed to elucidate the association between comorbidities, biological variables and lung SUVs in pre-therapeutic [18F]FDG-PET/CT. Methods: In this retrospective study, the pre-therapeutic SUV in [18F]FDG-PET/CT was measured in non-tumorous areas of both lobes of the lung. SUVMEAN, SUVMAX and SUV95 were compared to a multitude of patient characteristics and comorbidities with Spearman\'s correlation analysis, followed by a Bonferroni correction and multilinear regression. Results: In total, 240 patients with lung cancer were analyzed. An elevated BMI was significantly associated with increased SUVMAX (β = 0.037, p < 0.001), SUVMEAN (β = 0.017, p < 0.001) and SUV95 (β = 0.028, p < 0.001). Patients with chronic obstructive pulmonary disease (COPD) showed a significantly decreased SUVMAX (β = -0.156, p = 0.001), SUVMEAN (β = -0.107, p < 0.001) and SUV95 (β = -0.134, p < 0.001). Multiple other comorbidities did not show a significant correlation with the SUV of the non-tumorous lung. Conclusions: Failure to consider the influence of BMI and COPD on the pre-therapeutic SUV measurements may lead to an erroneous interpretation of the pre-therapeutic SUV and subsequent treatment decisions in patients with lung cancer.
摘要：
背景：关于非肿瘤肺组织的治疗前标准化摄取值（SUV）对治疗相关肺炎的风险评估的预后价值存在争议，大多数研究缺乏显著的相关性。然而,尚未系统评估患者合并症对治疗前肺部SUV的影响.因此，我们旨在阐明合并症之间的联系，治疗前[18F]FDG-PET/CT的生物学变量和肺SUV。方法：在这项回顾性研究中，[18F]FDG-PET/CT中的治疗前SUV在肺叶的非肿瘤区域进行了测量.苏丹,SUVMAX和SUV95通过Spearman的相关分析与多种患者特征和合并症进行比较，其次是Bonferroni校正和多元线性回归。结果：总的来说，对240例肺癌患者进行分析。BMI升高与SUVMAX升高显著相关(β=0.037,p<0.001),SUVMEAN(β=0.017,p<0.001)和SUV95(β=0.028,p<0.001)。慢性阻塞性肺疾病(COPD)患者SUVMAX显著降低(β=-0.156,p=0.001),SUVMEAN(β=-0.107,p<0.001)和SUV95(β=-0.134,p<0.001)。其他多种合并症与非肿瘤性肺的SUV没有显着相关性。结论：未能考虑BMI和COPD对治疗前SUV测量的影响可能会导致对肺癌患者治疗前SUV和随后的治疗决定的错误解释。
